HMGB1 and colorectal carcinoma: Our data cumulatively suggest that increased HMGB1 expression in CRC orchestrates a pro-tumour microenvironment, and HMGB1 may therefore be a therapeutic target of interest to improve endogenous anti-tumour immunity and chemosensitivity.